Literature DB >> 26470003

A complicated disease: what can be done to manage thalassemia major more effectively?

Raffaella Origa1, Alessandro Baldan2, Maria Marsella3, Caterina Borgna-Pignatti2.   

Abstract

Patients with thalassemia major suffer from many complications, but in the last two decades their lives have improved both in length and quality. We report herein the most common complications and the recent advances that have changed the course of this disease. Also, we report in detail some of the new therapeutic strategies already introduced in practice and briefly some that are still being developed.

Entities:  

Keywords:  HbF reactivation; JAK2; bisphosphonates; gene therapy; iron chelation; iron overload; magnetic resonance imaging; osteoporosis; sotatercept; stem cell transplantation

Mesh:

Year:  2015        PMID: 26470003     DOI: 10.1586/17474086.2015.1101339

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  2 in total

Review 1.  Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.

Authors:  Hadi Darvishi-Khezri; Hossein Karami
Journal:  Adv Ther       Date:  2021-03-04       Impact factor: 3.845

2.  β-Thalassemia Intermedia: Interaction of α-Globin Gene Triplication With β-thalassemia Heterozygous in Spain.

Authors:  Paloma Ropero; Fernando Ataúlfo González Fernández; Jorge M Nieto; Williana Melissa Torres-Jiménez; Celina Benavente
Journal:  Front Med (Lausanne)       Date:  2022-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.